# Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease

> **NCT05566678** · NA · WITHDRAWN · sponsor: **Philip Morris Products S.A.**

## Conditions studied

- Cardiovascular Diseases
- Smoking
- Tobacco Use
- Peripheral Arterial Disease
- Coronary Artery Disease

## Interventions

- **OTHER:** Cigarette
- **OTHER:** THS
- **OTHER:** Smoking Abstinence

## Key facts

- **NCT ID:** NCT05566678
- **Lead sponsor:** Philip Morris Products S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03-15
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was stopped before enrollment, after a feasibility review revealed we would be unable to measure the primary endpoint (flow mediated dilation - FMD) with a high degree of reproducibility and minimum variability in a multi-country setting.
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05566678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05566678, "Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05566678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*